The Latest Breaking News from Prostate Cancer

Why experts have advised against widespread prostate cancer screening

IN FULL

The Independent UK · May 28

Most UK men should not be offered prostate cancer screening, experts say

Government will consider committee’s guidance that says mass screening ‘likely to cause more harm than good’

The Guardian - UK · May 28

Prostate cancer screening: Final guidance recommends against testing all men

Only men with a specific gene variant and a family history of certain cancers should be screened, experts have said.

Evening Standard · May 28

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data

Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data and as it prepares for a planned biologics license application submission by the end of the year.

MarketBeat · May 20

How One Golfer Is Aiming To Set A New World Record Involving The Name 'Mark'

Mark Taylor is looking to raise £88,000 for Prostate Cancer UK by bringing 88 golfers called Mark together for a record breaking golf competition

Golf Monthly · May 20

New blood test could show if prostate cancer treatment is failing

The discovery could lead to personalised treatments for the disease

The Independent UK · May 15

Prostate cancer screening can save lives but ‘absolute benefit is small’, study says

Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment

The Guardian - UK · May 15

MDxHealth Q1 Earnings Call Highlights

MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company’s focus on prostate cancer diagnostic

MarketBeat · May 14

Abeona Therapeutics Q1 Earnings Call Highlights

Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company’s earnings call. Chi

MarketBeat · May 13

Prostate cancer overdiagnosis risk sharply rises after age 70 – new research

Over the past decade, millions of men without symptoms of prostate cancer have voluntarily undergone a prostate-specific antigen (PSA) test in the UK to find out if they might have prostate cancer.

The Conversation · Apr 28